Replies to post #147985 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

“Genomic signature found and to be reported at an upcoming conference. The signature allows them to accurately predict who will benefit most from 2-73. This way the data can be used in all future trials.”

This is quite a dramatic statement - do we interpret this statement that patients with these signature will benefit from A2-73 such that it will have positive impact on Alz?

If they PR it officially - it will be big news and lot of questions as to veracity of this claim

[falconer66a]

Experts, Tell How Anavex 2-73 Fails FDA Approval

From Jonjones' shareholder meeting notes:

Genomic signature found and to be reported at an upcoming conference. The signature allows them to accurately predict who will benefit most from 2-73. This way the data can be used in all future trials.

1. A genomic (DNA) signature has been found correlating to efficacy; thereby accurately predicting such.

2. Details to be announced at an upcoming conference.

3. Those who benefit most from Anavex 2-73 can now be predicted, detected, and selected.

4. Future Anavex 2-73 clinical trials will, necessarily and favorably, include only those pre-detected to have the DNA, genes, that respond positively to the molecule.

Jonjones, thanks so much for posting this seminal information.

With all of this, anyone want to tell us just how Anavex 2-73 fails the upcoming clinical trial for Alzheimer’s treatment and consequent FDA approval? Fill us in, please.

[Amatuer17]

JJ - thanks for documenting the minutes - appreciate it

The Genomic signature is a dramatic claim and material finding.
If he told the SH. In the meeting - shouldn’t this be informed to market as per requirements?
It is also an event that can move SP

“Genomic signature found and to be reported at an upcoming conference. The signature allows them to accurately predict who will benefit most from 2-73. This way the data can be used in all future trials. “

[Investor2014]

Jon Jones and Bourbon, thank you both for reporting and asking questions at the ASM!

“Genomic signature found and to be reported at an upcoming conference. The signature allows them to accurately predict who will benefit most from 2-73. This way the data can be used in all future trials. “

I am wondering, as before, whether the signature found is an indication that high A2-73 blood concentration will be reached by selecting those patients and thereby good response -can either of you tell or have a sense of that from the discussion with Missling?

The Ariana KEM analysis presentation indicated a strong correlation between drug blood concentration and response to A2-73 supporting that idea, whereas the outlier with low concentration responding very well indicates otherwise. This still puzzles me, but I guess I may have to wait for the answer just like everyone else :-)